Bank of N.T. Butterfield & Son (CVE:NTB) Price Target & New Coverage by Citigroup
The research firm Citigroup has has initiated coverage on Bank of N.T. Butterfield & Son (CVE:NTB)’s stock, rating it “Buy” while setting the price target at $32.0.
After the new coverage CVE:NTB is at the moment trading 0.00% lower at $0.00 as of 04:03 New York time. Bank of N.T. Butterfield & Son’s stock is up 35.25% over the last 200 days. It has outperformed the S&P 500, which has added 4.81% over the same time period.
CVE:NTB Price Chart & Trend
The stock price of Bank of N.T. Butterfield & Son has risen 35.25% over the last 200 days, and is in powerful up trend. In the last 50 and 100 days, Bank of N.T. Butterfield & Son is up 33.33% and up 38.24%, respectively. Our stocks momentum model is shown on the price chart below.
Bank of N.T. Butterfield & Son (CVE:NTB) Profile
Neptune Technologies & Bioressources Inc. is a solution provider of omega-3’s and other functional ingredients to branded marketers in the nutraceutical industry, primarily in North America. The Company is engaged in the development, manufacture and commercialization of marine-derived omega-3 fatty acids. The Company’s products include Krill-Based Nutraceutical Products, including Neptune Krill Oil (NKO), OCEANO3, Formulations Derived from NKO and Neptune Krill Aquatein (NKA); Other Nutraceutical Products, and Pharmaceutical Product Candidate (CaPre)-Acasti.
Bank of N.T. Butterfield & Son (CVE:NTB) closed at $0 yesterday. A total of shares of the company’s stock traded hands. This is down from average of 31,215 shares. Bank of N.T. Butterfield & Son has a 52 week low of $2.01 and a 52 week high of $4.46. The company has a market cap of $147.24M and a P/E ratio of 0.
Get the latest Bank of N.T. Butterfield & Son (CVE:NTB) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
Bank of N.T. Butterfield & Son - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.